Does Ductal Carcinoma in Situ Count in the Equation?
Patricia Kelly, RN, MS, AOCN Dallas, TX PatriciaKelly@TexasHealth.org Claus, E.B., Petruzella, S., Matloff, E., & Carter, D. (2005). Prevalence of BRCA1 and BRCA2 mutations in women diagnosed with ductal carcinoma in situ. JAMA, 293, 964-969. Study Summary The authors of this study present one of the first population-based case-controlled studies examining the prevalence of BRCA1 and BRCA2 mutations in women with a diagnosis of ductal carcinoma in situ (DCIS). A Connecticut Tumor Registry pool of 777 women, unselected for age, family history, or ethnicity, and with a diagnosis of pathology-confirmed DCIS, were interviewed and offered counseling and genetic testing for BRCA1 and BRCA2 mutations. After an initial counseling session, 369 women agreed to have genetic testing. Of the 369 cases, three women were found to have BRCA1 mutations, and nine women were found to have BRCA2 mutations, with one woman who had a mutation in both genes. The authors present two tables that describe the mu
